

ASX RELEASE | OSTEOPORE LIMITED

PROSPECTUS DESPATCHED

21 March 2023: Osteopore Limited (ASX: OSX) (**Osteopore**), a global leader in the manufacturing of regenerative implants that facilitate natural tissue regeneration, is pleased to announce that the prospectus dated 10 March 2023 (the **Prospectus**) and Application Form for its non-renounceable pro rata entitlement offer (**Entitlement Offer**) has today been despatched to eligible shareholders.

Eligible shareholders may access a copy of the Prospectus, along with their personalised Application Form by accessing: <https://events.miraqle.com/osx-offer>

Eligible shareholders who wish to take up their entitlement have until the closing date of the Entitlement Offer, being 5.00pm AEST on Tuesday, 4 April 2023, to accept their entitlement in full or in part.

Notifications have also been sent to ineligible shareholders pursuant to ASX Listing Rule 7.7.1(b).

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.